MediWound Ltd. (NASDAQ:MDWD - Free Report) - HC Wainwright issued their FY2029 earnings estimates for shares of MediWound in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst S. Ramakanth forecasts that the biopharmaceutical company will post earnings per share of $2.45 for the year. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for MediWound's current full-year earnings is ($2.66) per share.
MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the company posted ($0.19) earnings per share.
Several other brokerages also recently weighed in on MDWD. Craig Hallum started coverage on shares of MediWound in a report on Friday, February 28th. They set a "buy" rating and a $39.00 price target on the stock. StockNews.com raised shares of MediWound to a "sell" rating in a report on Friday.
Get Our Latest Research Report on MediWound
MediWound Price Performance
Shares of NASDAQ:MDWD traded down $0.04 during mid-day trading on Friday, reaching $16.23. 25,450 shares of the company traded hands, compared to its average volume of 89,899. The company's 50 day moving average price is $18.17 and its 200-day moving average price is $17.59. The firm has a market cap of $175.17 million, a PE ratio of -5.60 and a beta of 0.82. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00.
Institutional Investors Weigh In On MediWound
Institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in shares of MediWound in the fourth quarter worth $32,000. Russell Investments Group Ltd. boosted its holdings in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 1,162 shares during the last quarter. MetLife Investment Management LLC purchased a new position in shares of MediWound during the third quarter valued at about $89,000. Bank of America Corp DE increased its holdings in shares of MediWound by 38.0% in the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after purchasing an additional 2,178 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock worth $193,000 after purchasing an additional 739 shares during the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Read More
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
